EUR 0.0
(7.69%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -6.79 Million EUR | -199.91% |
2022 | -2.25 Million EUR | 80.8% |
2021 | -864 Thousand EUR | 18.45% |
2020 | -14.83 Million EUR | -63.21% |
2019 | -6.69 Million EUR | 32.26% |
2018 | -13.13 Million EUR | -13.09% |
2017 | -11.65 Million EUR | 4.28% |
2016 | -12.16 Million EUR | -1.27% |
2015 | -13.06 Million EUR | -132.74% |
2014 | -5.18 Million EUR | -47.94% |
2013 | -3.5 Million EUR | -6.41% |
2012 | -3.15 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -180.5 Thousand EUR | 0.0% |
2024 Q1 | -180.5 Thousand EUR | 87.95% |
2023 FY | - EUR | -224.27% |
2023 Q1 | -1.9 Million EUR | -112.89% |
2023 Q2 | -4.16 Million EUR | -119.21% |
2023 Q3 | -1.49 Million EUR | 64.03% |
2023 Q4 | -1.49 Million EUR | 0.0% |
2022 Q4 | -892.5 Thousand EUR | 0.0% |
2022 FY | - EUR | 80.8% |
2022 Q3 | -892.5 Thousand EUR | 78.97% |
2022 Q2 | -4.24 Million EUR | 0.0% |
2021 Q4 | -7.2 Million EUR | 0.0% |
2021 FY | - EUR | 18.45% |
2021 Q2 | -6.43 Million EUR | 0.0% |
2020 Q4 | -7.29 Million EUR | 0.0% |
2020 FY | - EUR | -63.21% |
2020 Q2 | -9.78 Million EUR | 0.0% |
2019 FY | - EUR | 32.26% |
2019 Q2 | -6.72 Million EUR | 0.0% |
2019 Q4 | -7.01 Million EUR | 0.0% |
2018 Q4 | -7.29 Million EUR | 0.0% |
2018 FY | - EUR | -13.09% |
2017 FY | - EUR | 4.28% |
2016 FY | - EUR | -1.27% |
2015 FY | - EUR | -132.74% |
2014 Q3 | -953 Thousand EUR | 0.0% |
2014 FY | - EUR | -47.94% |
2014 Q4 | -1.79 Million EUR | -88.04% |
2013 Q4 | -1.17 Million EUR | 0.0% |
2013 FY | - EUR | -6.41% |
2012 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Nicox S.A. | -16.23 Million EUR | 58.148% |
European Medical Solutions | 59 Thousand EUR | 11618.644% |
FERMENTALG | -10.51 Million EUR | 35.338% |
argenx SE | -199.5 Million EUR | 96.594% |
Celyad Oncology SA | -7.76 Million EUR | 12.457% |
Hyloris Pharmaceuticals SA | -14.98 Million EUR | 54.633% |
Onward Medical N.V. | -35.23 Million EUR | 80.712% |
Oxurion NV | -16.72 Million EUR | 59.376% |
PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 70.362% |
Financière de Tubize SA | 184.57 Thousand EUR | 3782.052% |
UCB SA | 1.26 Billion EUR | 100.536% |